# Round 3 — Claude's final position

Round 2 dropped all ten round-1 findings (verified in the files) and raised one new one, F-011, which I
accept and have fixed. No open findings remain on my side.

**F-011 — Control-2 still explained the lower-tail direction beyond the decomposition. ACCEPTED.** I removed
the unmeasured causal clause ("restricting to twelve diseases interacting with the permutation" as a "modest
consequence"). The sentence now reads: the direction "is a feature of this restricted twelve-disease
permutation setup; the one component we actually measured, a per-gene concentration effect, is small (2.39
vs. 2.44 distinct disease labels per passing gene), so we report the figures but do not interpret the
mechanism of the direction further." Control 2 now asserts only what the artifact measures: (i)
substrate-inherited stringency (null pass rate 0.99%), (ii) label-dependence (5.6 SD below null, lower-tail
p ≈ 5×10⁻⁴, upper-tail p = 1.0), and (iii) a small, reported-but-uninterpreted per-gene cardinality figure.

**Consolidated position.** §4 now: (a) has every quantitative claim traceable to a primary artifact
(`sensitivity_results.json` + CS delta-0 reproduction; `stage1/sweep_Stim8hr.json`; `stage3/stage3_cis.json`;
`perturbseq-qc` receipts; `replication_report`); (b) uses calibrated language throughout, with the one
"validated" slip removed and §1's "proves" corrected; (c) reads the Control-2 result honestly on both tails,
crediting the disease-hop stringency to the substrate rather than the referee; (d) scopes the STAT6
cis-refutation to the perturbation signal and the cluster-membership artifact, explicitly leaving the
GWAS-label LD question open; (e) scopes the replication claim to lab-level rather than per-agent-per-number.

**Preserve-intent — final check.** The three protected claims are intact and, if anything, sharper: the
falsification thesis (confident receipt-backed NO; untested≠refuted) is unchanged; the Control-2 honesty was
*strengthened* (weaker mechanism, correct tails) not sanded into a false positive; the self-audit is
role/model/checkpoint, not cross-vendor. No novelty was lost to convergence.

Framing question, answered: §4 is now defensible to a hostile FRMA/LBD reviewer on the axes tested —
number traceability, calibrated language, and both-tails-honest Control-2 interpretation.
